Michael Schweizer, MD

Michael Schweizer, MD

Assistant Professor, Medicine, Oncology
University of Washington School of Medicine
Assistant Member
Clinical Research Division


M.D., Temple University School of Medicine, 2008.
B.S., University of Delaware, Chemical Engineering, 2004

Research Focus:

  • Translational prostate cancer research
  • Novel therapeutics/drug development

Clinical Expertise:

Genitourinary oncology (Prostate, bladder, kidney and testicular cancers)

Current Studies

  • A Phase II neoadjuvant study of enzalutamide, abiraterone acetate, prednisone, dutasteride and degarelix in men with localized prostate cancer pre-prostatectomy
  • A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer.

Recent Publications

1)    Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate. 2014 Aug 31.
2)    Suzman DL, Luber B, Schweizer MT, et al. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate. 2014 Jul 22
3)    Schweizer MT, Antonarakis ES. Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl. 2014 May-Jun; 16(3): 334-40.
4)    Nadal R, Schweizer MT, Kryvenko ON, et al. Small Cell Carcinoma of the Prostate. Nat Rev Urol. 2014 Apr; 11(4): 213-9.
5)    Schweizer MT, Drake CG. Immunotherapy for Prostate Cancer: Recent Developments and Future Challenges. Cancer Metastasis Rev. 2014 Jan 30.
6)    Schweizer MT, Zhou XC, Wang H, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. European Urology. 2014 Jan 24.
7)    Schweizer MT, Lin J, Blackford A, Bardia A, King A, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. Pharmacodynamic Study of Disulfiram in Men with Non-metastatic Recurrent Prostate Cancer. Prostate Cancer Prostatic Dis. 2013 Dec; 16 (4): 357-61.
8)    Schweizer MT, Zhou XC, Wang H, et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol. 2013 Nov; 24 (11): 2881-6.
9)    Schweizer MT, Huang P, Kattan MW, et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials. Cancer. 2013 Oct 15; 119 (20): 3610-8.
10)    Schweizer MT, Carducci MA. From Bevacizumab to Tasquinimod: Angiogenesis as a Therapeutic Target in Prostate Cancer. Cancer Journal. 2013 Jan; 19(1): 99-106.
11)    Schweizer MT, Antonarakis ES. The full potential of abiraterone acetate:  a “hat trick” of clinical benefits. The Lancet Oncology. 2012 Dec;13(12):1173-4.
12)    Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: A new era of hormonal therapies is borne. Therapeutic Advances in Urology 4(4):167-78, 2012
13)    Schweizer MT, Mehta R, Salgia R, et al. Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma. J Clin Oncol 29:e598-600, 2011

Additional Links & Information

Related Labs & Projects

View all labs & projects >
Michael Schweizer MD

Contact Information

(206) 606-6252
(206) 606-2042
Additional contact

Mail Stop: G6-075